Healthcare / Medical Instruments & SuppliesNasdaqCM
$2.00
-0.03 (-1.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 27% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.9M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
100/100
+79.6% upside
5Y CAGR
+15.6%
100/100
Data QA
100/100
SEC 100%
Sin guardar todavía.
Market Cap
$134M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.9%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.00x
Latest source
SEC-backed
Margin decomposition
Último año: revenue — · net income $-13.1M · FCF $-13.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025SEC | 2024SEC | 2023SEC | 2022SEC | 2021SEC | 2020SEC | 2019SEC | 2018SEC | 2017SEC | 2016SEC | 2015SEC | 2014SEC | 2013SEC | 2012SEC | 2011SEC | 2010SEC | 2009SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | $116887.00 | $1.0M | $172297.00 | $1.4M | $1.2M | $1.4M | $992870.00 |
| Net Income | $-13.1M | $-13.1M | $-11.4M | $-10.7M | $-13.2M | $-11.3M | $-9.2M | $-7.2M | $-7.3M | $-7.6M | $-9.7M | $-921000.00 | $-32.7M | $-26.4M | $-28.5M | $-21.3M | $-25.2M | $-27.0M |
| EBITDA | $-14.7M | $-14.7M | $-11.5M | $-10.0M | $-13.3M | $-11.3M | $-9.0M | $-7.2M | $-7.2M | — | — | $2.0M | $-29.6M | $-27.0M | $-20.9M | $-26.9M | $-27.8M | $-27.7M |
| EPS | -0.29 | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 514.6% | 80.8% | 82.4% | 88.2% | 73.7% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | 782.8% | -3053.2% | -16304.8% | -1601.5% | -2300.1% | -2057.5% | -2958.9% |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | -787.9% | -3234.1% | -15345.1% | -2082.8% | -1747.3% | -1769.0% | -2722.0% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.05 | 0.06 | — | — | — | — | — | — | — | — | 0.01 | 0.02 | 0.05 | 0.05 | — |
| Current Ratio | 22.59 | 22.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-13.1M | $-13.1M | $-8.9M | $-8.6M | $-11.6M | $-9.4M | $-7.3M | $-6.7M | $-5.5M | $-4.9M | $-811000.00 | $-767000.00 | $-28.3M | $-28.0M | $-19.9M | $-22.4M | $-25.4M | $-25.4M |
| Returns | ||||||||||||||||||
| ROE | -16.9% | -16.9% | -324.2% | -238.6% | -180.7% | -78.7% | -37.7% | -23.0% | -545.9% | -76.0% | -569.8% | -1439.1% | -3820.5% | -176.8% | -203.7% | -198.9% | -163.1% | -88.6% |
| Valuation | ||||||||||||||||||
| P/B | 1.01 | 1.01 | 7.58 | 3.88 | 1.70 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | — | -88.5% | 487.6% | -87.4% | 12.1% | -14.5% | 43.7% | — |
| EPS Growth | 60.3% | 60.3% | 30.5% | 42.0% | -13.8% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.73 → -0.29
Residual
-21.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.